Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium
<p><strong>Aims/hypothesis</strong></p> <p>Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of fol...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer
2019
|
| _version_ | 1797072381153378304 |
|---|---|
| author | Koivula, RW Forgie, IM Kurbasic, A Viñuela, A Heggie, A Giordano, GN Hansen, TH Hudson, M Koopman, ADM Rutters, F Siloaho, M Allin, KH Brage, S Brorsson, CA Dawed, AY De Masi, F Groves, CJ Kokkola, T Mahajan, A Perry, MH Rauh, SP Ridderstråle, M Teare, HJA Thomas, EL Tura, A Vestergaard, H White, T Adamski, J Bell, JD Beulens, JW Brunak, S Dermitzakis, ET Froguel, P Frost, G Gupta, R Hansen, T Hattersley, A Jablonka, B Kaye, J Laakso, M McDonald, TJ Pedersen, O Schwenk, JM Pavo, I Mari, A McCarthy, MI Ruetten, H Walker, M Pearson, E Franks, PW Imi Direct Consortium |
| author_facet | Koivula, RW Forgie, IM Kurbasic, A Viñuela, A Heggie, A Giordano, GN Hansen, TH Hudson, M Koopman, ADM Rutters, F Siloaho, M Allin, KH Brage, S Brorsson, CA Dawed, AY De Masi, F Groves, CJ Kokkola, T Mahajan, A Perry, MH Rauh, SP Ridderstråle, M Teare, HJA Thomas, EL Tura, A Vestergaard, H White, T Adamski, J Bell, JD Beulens, JW Brunak, S Dermitzakis, ET Froguel, P Frost, G Gupta, R Hansen, T Hattersley, A Jablonka, B Kaye, J Laakso, M McDonald, TJ Pedersen, O Schwenk, JM Pavo, I Mari, A McCarthy, MI Ruetten, H Walker, M Pearson, E Franks, PW Imi Direct Consortium |
| author_sort | Koivula, RW |
| collection | OXFORD |
| description | <p><strong>Aims/hypothesis</strong></p> <p>Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).</p> <br/> <p><strong>Methods</strong></p> <p>From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6–24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe.</p> <br/> <p><strong>Results</strong></p> <p>Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m2; fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants’ clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 517) were treated by lifestyle modification and 34% (n = 272) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m2; fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the participants’ clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l.</p> <br/> <p><strong>Conclusions/interpretation</strong></p> <p>The IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.</p> |
| first_indexed | 2024-03-06T23:07:00Z |
| format | Journal article |
| id | oxford-uuid:642e08cd-e7ce-4082-baeb-ada90f7158da |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:07:00Z |
| publishDate | 2019 |
| publisher | Springer |
| record_format | dspace |
| spelling | oxford-uuid:642e08cd-e7ce-4082-baeb-ada90f7158da2022-03-26T18:17:24ZDiscovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT ConsortiumJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:642e08cd-e7ce-4082-baeb-ada90f7158daEnglishSymplectic Elements at OxfordSpringer2019Koivula, RWForgie, IMKurbasic, AViñuela, AHeggie, AGiordano, GNHansen, THHudson, MKoopman, ADMRutters, FSiloaho, MAllin, KHBrage, SBrorsson, CADawed, AYDe Masi, FGroves, CJKokkola, TMahajan, APerry, MHRauh, SPRidderstråle, MTeare, HJAThomas, ELTura, AVestergaard, HWhite, TAdamski, JBell, JDBeulens, JWBrunak, SDermitzakis, ETFroguel, PFrost, GGupta, RHansen, THattersley, AJablonka, BKaye, JLaakso, MMcDonald, TJPedersen, OSchwenk, JMPavo, IMari, AMcCarthy, MIRuetten, HWalker, MPearson, EFranks, PWImi Direct Consortium<p><strong>Aims/hypothesis</strong></p> <p>Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).</p> <br/> <p><strong>Methods</strong></p> <p>From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6–24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe.</p> <br/> <p><strong>Results</strong></p> <p>Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m2; fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants’ clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 517) were treated by lifestyle modification and 34% (n = 272) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m2; fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the participants’ clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l.</p> <br/> <p><strong>Conclusions/interpretation</strong></p> <p>The IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.</p> |
| spellingShingle | Koivula, RW Forgie, IM Kurbasic, A Viñuela, A Heggie, A Giordano, GN Hansen, TH Hudson, M Koopman, ADM Rutters, F Siloaho, M Allin, KH Brage, S Brorsson, CA Dawed, AY De Masi, F Groves, CJ Kokkola, T Mahajan, A Perry, MH Rauh, SP Ridderstråle, M Teare, HJA Thomas, EL Tura, A Vestergaard, H White, T Adamski, J Bell, JD Beulens, JW Brunak, S Dermitzakis, ET Froguel, P Frost, G Gupta, R Hansen, T Hattersley, A Jablonka, B Kaye, J Laakso, M McDonald, TJ Pedersen, O Schwenk, JM Pavo, I Mari, A McCarthy, MI Ruetten, H Walker, M Pearson, E Franks, PW Imi Direct Consortium Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium |
| title | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium |
| title_full | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium |
| title_fullStr | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium |
| title_full_unstemmed | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium |
| title_short | Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium |
| title_sort | discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes descriptive characteristics of the epidemiological studies within the imi direct consortium |
| work_keys_str_mv | AT koivularw discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT forgieim discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT kurbasica discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT vinuelaa discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT heggiea discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT giordanogn discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT hansenth discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT hudsonm discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT koopmanadm discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT ruttersf discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT siloahom discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT allinkh discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT brages discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT brorssonca discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT daweday discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT demasif discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT grovescj discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT kokkolat discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT mahajana discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT perrymh discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT rauhsp discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT ridderstralem discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT tearehja discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT thomasel discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT turaa discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT vestergaardh discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT whitet discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT adamskij discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT belljd discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT beulensjw discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT brunaks discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT dermitzakiset discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT froguelp discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT frostg discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT guptar discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT hansent discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT hattersleya discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT jablonkab discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT kayej discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT laaksom discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT mcdonaldtj discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT pederseno discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT schwenkjm discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT pavoi discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT maria discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT mccarthymi discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT ruettenh discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT walkerm discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT pearsone discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT frankspw discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium AT imidirectconsortium discoveryofbiomarkersforglycaemicdeteriorationbeforeandaftertheonsetoftype2diabetesdescriptivecharacteristicsoftheepidemiologicalstudieswithintheimidirectconsortium |